In the clinical trials of FOLFIRINOX with CCR2 antagonists PF-04136309 and CCX872, respectively, better local tumor control rate was observed (NCT01413022), and the overall survival rate was also improved compared with chemotherapy alone (NCT02345408) (Poh and Ernst, 2021). Here, CCR2 is linked to neoplasm.